iBio Inc. Annual report pursuant to Section 13 and 15(d)

Share-Based Compensation (Tables)

12 Months Ended

Jun. 30, 2021

The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations (in thousands):

The following table summarizes all stock option activity during the years ended June 30, 2021 and 2020:


				Weighted-
		Weighted-		average
		average		Remaining	Aggregate
	Stock	Exercise		Contractual	Intrinsic Value
	Options	Price		Term (in years)	(in thousands)
Outstanding as of July 1, 2019	1,346,519	$	1.45	6.1	$	—
Granted	2,383,300		1.11	—		—
Exercised	(139,392)		0.93	—		—
Forfeited/expired	(114,654)		3.32	—		—
Outstanding as of June 30, 2020	3,475,773	$	1.18	8.2	$	4,042
As of June 30, 2020, vested and expected to vest	3,424,064	$	1.18	8.3	$	3,987

Exercisable as of June 30, 2020	983,442	$	1.40	4.6	$	1,221

Outstanding as of June 30, 2020	3,475,773	$	1.18	8.2	$	4,042
Granted	5,240,000		1.44	—		—
Exercised	(53,687)		1.02	—		—
Forfeited/expired	(119,933)		2.45	—		—
Outstanding as of June 30, 2021	8,542,153	$	1.31	8.8	$	1,995
As of June 30, 2021, vested and expected to vest	8,520,349	$	1.31	8.8	$	1,988

Exercisable as of June 30, 2021	1,933,460	$	1.11	6.4	$	890

The following table summarizes information about options outstanding and exercisable at June 30, 2021:


	Options Outstanding and Exercisable
		Weighted-	Weighted-
		Average	Average
	Number	Remaining Life	Exercise		Number
	Outstanding	In Years	Price		Exercisable
Exercise prices:
$0.90 - $1.37	5,832,319	8.5	$	1.18	1,561,957
$1.41 - $2.12	2,700,000	9.5		1.56	361,669
$2.53 - $3.80	500	6.7		2.53	500
$7.30 - $10.95	9,334	0.9		8.59	9,334

	8,542,153	8.8	$	1.31	1,933,460

The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:


	2021		2020
Weighted average risk-free interest rate	0.39 - 1.02	%	0.60	%
Dividend yield	0	%	0	%
Volatility	119.46 - 126.55	%	97.5	%
Expected term (in years)	6		9